Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Low Risk

Score: 5/100

Failure Rate

0.0%

0 terminated/withdrawn out of 6 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

33%

2 trials in Phase 3/4

Results Transparency

100%

1 of 1 completed trials have results

Key Signals

1 with results

Enrollment Performance

Analytics

Phase 1

3(50.0%)

Phase 3

2(33.3%)

Phase 2

1(16.7%)

6Total

Phase 1(3)

Phase 3(2)

Phase 2(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (6)

Showing 6 of 6 trials

NCT06886139Phase 2Not Yet Recruiting

A Phase 2 Study of TRS005 in Patients With CD20-positive R/R DLBCL.

Role: lead

NCT07035379Phase 1Not Yet Recruiting

A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL

Role: lead

NCT05395533Phase 1Active Not Recruiting

A Phase 1 Study of TRS005 in Patients With R/R CD20-positive B-NHL.

Role: lead

NCT05378867Phase 3Unknown

A Study Assessing the Interchangeability Between TRS003 and Bevacizumab® For CRC

Role: lead

NCT04416035Phase 3Unknown

A Study to Compare the Similarity in Efficacy and Safety Between TRS003 and China-approved Bevacizumab® in NSCLC

Role: lead

NCT03882424Phase 1Completed

A Study to Compare Pharmacokinetic and Safety of TRS003 to China-approved Bevacizumab and US-licensed Avastin®

Role: lead

All 6 trials loaded